Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Spreen

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
The Lancet. HIV|April 1, 2021
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR studyChloe Orkin, Shinichi Oka, Patrick Philibert, et al.
Lancet (London, England)|April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialSinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 2, 2020
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR TrialsGiuliano Rizzardini, Edgar T Overton, Chloe Orkin, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
The Lancet. HIV|April 1, 2021
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR studyChloe Orkin, Shinichi Oka, Patrick Philibert, et al.
Lancet (London, England)|April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialSinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 2, 2020
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR TrialsGiuliano Rizzardini, Edgar T Overton, Chloe Orkin, et al.
Pageof 5